PI3K/Akt signaling-dependent EMT has been reported to facilitate resistance to chemotherapy in human multiple myeloma 56, cisplatin resistance in hepatocellular carcinoma cells 57 and TAM resistance in breast cancer cells 58. Here, AKT1 is linked to hepatocellular carcinoma.